Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review assesses the current literature on COVID-19's effects on male sexual and reproductive health, highlighting significant research gaps and providing guidance for patient counseling.

In this case report, a male patient's semen parameters improved after discontinuing a 1-mg dose of finasteride, suggesting that stopping the medication may benefit infertile men with previous sperm production issues.

This article discusses concerns and recommendations from a French-speaking andrology society regarding COVID-19's potential impact on men's reproductive health and calls for further research in this area.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This study reviews the mechanisms by which SARS-CoV-2 may impact male fertility, noting potential disruptions in spermatogenesis and hormone secretion, and underscores the need for follow-up in recovered men.

This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

This case report describes a 40-year-old man whose secondary infertility, observed after prolonged finasteride use for hair loss, resolved following discontinuation of the drug, resulting in a live birth.

This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This study describes the first reported case of a successful full-term pregnancy and live birth after long-term use of finasteride, suggesting it may not prevent normal conception despite initial severe oligospermia after discontinuation.

Stopping finasteride can improve sperm count in infertile men.

BMI should be considered in future research on dutasteride's effects on fertility.

This study observed that American men seeking reproductive urology evaluation were older, more obese, and had a longer duration of infertility than Canadian men, with significant lifestyle and referral differences between the countries.

Finasteride is risky during pregnancy, but the chance of harm from a male partner taking it is low if handled safely.

Pregnant women should avoid handling crushed finasteride tablets, but exposure through a male partner's semen is minimal.

This study found no significant difference in semen parameters or reproductive hormone levels between men taking low-dose finasteride for androgenic alopecia and those not on the medication.

A thorough initial check-up is essential before sperm banking to ensure the best chance of preserving good quality sperm.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

Oral propranolol successfully treated a baby's skin growth and ulceration linked to PELVIS syndrome.

In this study, plasmatherapy was found to improve immune status indicators in patients with vitiligo, particularly benefiting those with segmental vitiligo by normalizing immune markers and reducing IL-6 levels, suggesting its potential as an adjunct treatment to slow depigmentation progression.

In this study, stable types of leucoderma such as segmental vitiligo and piebaldism showed 100% repigmentation after melanocyte transplantation, suggesting surgery as the preferred method for these conditions.

This study reported successful repigmentation without scarring in patients with localized and segmental vitiligo after epidermal grafting, but the Koebner phenomenon hindered similar results in some with generalized vitiligo.

In this study, single hair grafting was reported to be an effective treatment for localized/segmental vitiligo, notably in hairy skin areas, with repigmentation observed in 82% of those cases.

This report presents the second known case of erythema nodosum without typical associated conditions, which could be linked to mycoplasma infection, although no testing was conducted to confirm this in the patient.

This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.

This study observed that individuals with premature hair graying had lower levels of certain serum nutrients and lifestyle factors like stress and smoking may contribute; hair oiling appeared protective.

This study found that a combined pattern of repigmentation was most commonly observed in vitiligo, with a new 'medium spotted' pattern proposed for areas with few hair follicles.

This meeting report provides an overview of recent evidence on vitiligo treatments, indicating a lack of standardized outcome measures and emphasizing the need for more consistent clinical trials.